Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis

Final draft guidance

Final draft guidance (PDF 314 KB)

Committee papers (PDF 1.04 MB)

Public committee slides (PDF 349 KB)

Equality impact assessment (PDF 138 KB)

Appeal

Janssen : Appeal letter (MSWord 99 KB)

Myeloma UK : Appeal letter (MSWord 66 KB)

Janssen : Scrutiny letter (MSWord 88 KB)

Myeloma UK : Scrutiny letter (MSWord 90 KB)

Janssen : Response to scrutiny letter (MSWord 98 KB)

Myeloma UK : Response to scrutiny letter (MSWord 62 KB)

Janssen : Final scrutiny letter (MSWord 74 KB)

Myeloma UK : Final scrutiny letter (MSWord 71 KB)

Appeal decision (PDF 301 KB)

Final draft guidance

Final appraisal document (PDF 303 KB)

Committee papers (PDF 831 KB)

Public committee slides (PDF 1.26 MB)

Draft guidance: 1

Public committee slides (PDF 1.14 MB)

Committee papers (PDF 4.28 MB)

Appraisal consultation document (online commenting)

Appraisal consultation document (PDF version) (PDF 333 KB)

Committee papers Summary of Information for Patients (SIP) (PDF 1.16 MB)

Committee meeting: 3

Topic Register of Interest (MSWord 43 KB)

Equality impact assessment (Scoping) (PDF 131 KB)

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 281 KB)

Final scope (PDF 179 KB)

Final stakeholder list (PDF 192 KB)

Draft scope post referral (PDF 183 KB)

Draft matrix post referral (PDF 190 KB)